While chemotherapy provides useful palliation, advanced lung cancer remains incurable
since those tumors that are initially sensitive to therapy rapidly develop acquired resistance …

Lung cancer is the leading cause of cancer mortality worldwide. There have been only slight
improvements in early diagnosis and survival, reflecting limited advances in screening and …

Background Genetic polymorphisms of genes involved in DNA repair and glutathione
metabolic pathways may affect patients' response to platinum-based chemotherapy. We …

Background Platinum-based therapy is pivotal to the treatment of advanced non-small cell
lung Cancer (NSCLC). Excision repair cross-complementation group 1 (ERCC1) is a key …

Background Interindividual variation in genetic background may influence the response to
chemotherapy and overall survival for patients with advanced-stage non–small cell lung …

The prognostic significance of inherited genetic variants in advanced-stage non-small cell
lung cancer (NSCLC) patients remains unknown. In this study, we genotyped 271 817 single …

Head and neck cancer (HNC) patients have variable prognoses even within the same
clinical stage and while receiving similar treatments. The number of studies of genetic …

NSCLC is the leading cause of cancer-related death in the US. Patients with NSCLC are
mostly treated with platinum-based chemotherapy, often in combination with radiation …

The published data on the predictive value of polymorphism of ERCC1 and XPD in patients
with advanced non-small cell lung cancer receiving platinum-based chemotherapy are …

BACKGROUND: Cisplatin toxicity severely obstacles successful chemotherapy in lung
cancer patients. Cisplatin uptake is considered as one of the major factors contributing to the …